Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
| KRYS Stock | USD 159.29 1.20 0.75% |
Slightly above 67% of Krystal Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Krystal Biotech suggests that many traders are alarmed. Krystal Biotech's investing sentiment can be driven by a variety of factors including economic data, Krystal Biotech's earnings reports, geopolitical events, and overall market trends.
Krystal |
Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27 percent ORR and 73 percent DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 -- Krystal Biotech, Inc. , a commercial-stage biotechnology company, an
Read at finance.yahoo.com
 |
Krystal Biotech Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Krystal Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Krystal Biotech Fundamental Analysis
We analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Krystal Biotech is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Krystal Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Krystal Biotech stock to make a market-neutral strategy. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics with similar companies.
Peers
Krystal Biotech Related Equities
| MGTX | MeiraGTx Holdings | 1.64 | ||||
| APLS | Apellis Pharmaceuticals | 0.85 | ||||
| RYTM | Rhythm Pharmaceuticals | 1.68 | ||||
| RGNX | Regenxbio | 5.84 |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.